What Fluzone Quadrivalent Treats: Main Uses and Benefits

Fluzone Quadrivalent is commonly used for active immunization to prevent the infectious disease known as seasonal influenza. Its primary role is related to active immunization for the prevention of the seasonal influenza disease caused by the specific virus strains contained in the vaccine.

The vaccine may assist with providing prophylaxis against two Influenza A strains and two Influenza B strains. This prophylactic approach is applied in the context of conditions characterized by periods of heightened symptoms and symptoms related to systemic imbalance, such as debilitating high fever, pronounced body aches, and fatigue. The use of this vaccine supports the patient by mitigating the potential impact of the flu illness.

“This preventative strategy may assist with reducing the potential for symptoms that interfere with daily functioning, and supports general well-being.”

The vaccine is commonly used as a routine, annual clinical strategy for all persons six months of age and older. Its application may help manage the risk of developing severe symptoms that interfere with daily functioning and contributes to easing the overall symptom load during a difficult symptomatic phase.

---

Quick Fact: Prophylaxis for Systemic Discomfort and Respiratory Symptoms

Regulatory References

1. NIH DailyMed Prescribing Information

The official eligibility for Fluzone Quadrivalent is determined by age and specific medical history, as defined in government regulatory labeling. The vaccine is approved for use in persons 6 months of age and older. Use is not approved for infants younger than 6 months.

Contraindications and Restrictions

Category	Official Regulatory Statement
Absolute Contraindication	A history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous dose of any influenza vaccine.
Conditional Use	If Guillain-Barré Syndrome (GBS) occurred within 6 weeks of a prior influenza vaccination, administration requires a careful risk-benefit evaluation.
Limited Response	For immunocompromised persons, including those receiving immunosuppressive therapy, the official label notes the expected immune response may not be obtained.

Eligibility in the elderly ( 65 years of age) is permitted, but the official label notes that antibody responses are lower compared to younger adults. The regulatory prescribing information provides limited human data to assess vaccine-associated risk during pregnancy and no specific data on the effects during lactation.

Fluzone Quadrivalent Interactions with other medicines and products

---

Before receiving the Fluzone Quadrivalent vaccine, it is important to inform your healthcare provider about all medicines you are taking, including prescription drugs, over-the-counter medications, vitamins, and herbal supplements. While Fluzone Quadrivalent is not known to have numerous direct drug-drug interactions that cause immediate adverse effects, its effectiveness can be influenced by certain types of medications.

Impact on Vaccine Effectiveness

Immunosuppressive Treatments

The most clinically significant interaction involves immunosuppressive treatments. These medicines—which include corticosteroids (like prednisone) and treatments for cancer, psoriasis, rheumatoid arthritis, and organ transplant rejection—weaken the immune system. When the immune system is compromised, the body may not develop the expected immune response to the vaccine, potentially resulting in reduced protection against the influenza virus. Healthcare providers should assess the patient's immune status and may recommend an alternative timing for vaccination.

Concomitant Administration

Fluzone Quadrivalent must not be mixed with any other vaccine or medicinal product in the same syringe. However, it may generally be given at the same time as other vaccines, provided that different injection sites and different needles/syringes are used. Always follow the administration guidance provided by a healthcare professional.

Fluzone Quadrivalent functions as an active immunizing agent by introducing inactivated influenza virus antigens into the host system, typically via intramuscular injection into skeletal muscle tissue. The biological targets are professional antigen-presenting cells (APCs), such as dendritic cells and macrophages, located at the injection site.

These APCs internalize the viral hemagglutinin (HA) and other surface antigens from the four included influenza virus strains (two A subtypes and two B lineages). The APCs then process and present the antigens via major histocompatibility complex (MHC) molecules to T-lymphocytes and B-lymphocytes in local lymph nodes. This molecular interaction triggers T-helper cell activation and subsequent B-cell proliferation and differentiation into plasma cells and memory B cells.

The downstream cascade involves the synthesis and secretion of specific neutralizing antibodies that target the viral surface protein hemagglutinin. The system-level physiological consequence is the establishment of a humoral immune response, characterized by a circulating antibody population capable of binding to the four specific HA antigens, thereby functionally neutralizing potential future viral particles expressing those homologous HA antigens.

How to Use Fluzone Quadrivalent (Influenza Vaccine, Quadrivalent, Inactivated)

Fluzone Quadrivalent is administered only by intramuscular (IM) injection. It must not be injected into a vein, under the skin, or between the layers of skin.

Dosing and Schedule

The dosage volume and number of doses required depend on the recipient's age and prior influenza vaccination history.

Age Group	Prior Vaccination History	Dose Volume	Schedule
9 years and older	Any	0.5 mL	Single dose annually
6 months - 8 years	Not previously vaccinated	0.5 mL or 0.25 mL	Two doses, given at least 4 weeks apart
6 months - 8 years	Previously vaccinated	0.5 mL or 0.25 mL	Single dose annually

Preparation and Administration

1. Preparation: The vaccine should be visually inspected for discoloration or particulate matter before use. If observed, do not use. Shake the syringe or vial well immediately prior to drawing up or administering the dose.
2. Administration Site: The injection site depends on age:
   • Adults and older children (geq 36 months): The deltoid muscle in the upper arm.
   • Infants and young children (6 months - 35 months): The anterolateral aspect of the thigh muscle.

Do not inject the vaccine into the gluteal area. The full dosing series, including the required two-dose series for certain younger children, must be followed to complete the usage protocol.

Evidence for Prophylaxis and Prevention of Seasonal Influenza

This section will summarize the research structure, including randomized clinical trials and real-world evidence studies, that examined the vaccine's function as an immunizing agent and explored patterns related to laboratory-confirmed seasonal influenza.

The primary research approach involved randomized, controlled clinical trials (RCTs) and immunogenicity studies. Researchers utilized these trials to observe how the body's immune system responded to the vaccine's components. Outcomes examined included post-vaccination Geometric Mean Antibody Titers (GMTs) and Seroconversion Rates (SCRs). Research also monitored the incidence of laboratory-confirmed influenza (LCI) and influenza-like illness (ILI) in the study populations.

The research was evaluated in populations including healthy adults and children as young as 6 months of age. The findings derived from these studies describe patterns observed in the measured antibody levels and show that a specific immune response was observed following administration. Real-world evidence (RWE) studies also report patterns related to the observed rates of LCI within communities during specific influenza seasons.

However, certainty remains low regarding the clinical outcomes examined across all possible variables. The research describes that the measured effectiveness observed in any given year can vary widely due to the annual change in circulating virus strains. Furthermore, many trials primarily focused on the immune response rather than direct, long-term clinical outcomes. Limited direct comparative evidence is lacking from large-scale RCTs that assess this specific standard-dose quadrivalent vaccine's long-term outcomes.

Evidence Related to Severe Outcomes and Systemic Symptoms

This part will detail the research that evaluated patterns concerning severe clinical events, such as hospitalizations and emergency room visits, which are surrogates for severe systemic discomfort associated with the flu.

Research has explored how the vaccine was associated with patterns of severe outcomes related to the flu. These studies, predominantly observational in design (RWE), included cohorts where symptoms become more noticeable, examining temporary physiological imbalance. Outcomes monitored physiological strain or stress, specifically monitoring rates of hospitalizations and emergency room visits linked to influenza and related complications.

Study Design and Comparative Immunogenicity

This section will outline the structure of comparative studies, primarily focusing on immunogenicity trials that measured antibody levels (titers) and seroconversion rates against the four virus strains, often comparing the quadrivalent vaccine to older trivalent formulations.

Research examined the comparison of the quadrivalent formulation to its predecessor, the trivalent vaccine (TIV). These studies explored short-term symptom changes, with immune outcomes related to physiological strain or stress measured at defined time intervals. Studies reported measurements of both Geometric Mean Titers and Seroconversion Rates, noting that the measured immune response to the shared strains was comparable between the two formulations. Immunogenicity findings, while necessary for licensure, do not provide direct insight into clinical effectiveness.

Research in Special Populations

This content will describe the specific research available for distinct age groups, including studies focused on children (6 months to <9 years) and adults, outlining which populations were included in the major clinical and observational trials.

The vaccine was evaluated in special populations, primarily focusing on defined age groups. Research also examined adults aged 18 years and older, with the ge 65 age group sometimes included as a comparison cohort in studies of other specialized vaccine types. However, evidence is limited for certain groups. Data for certain groups, such as those with specific comorbidities, remain insufficient within the primary standard-dose Fluzone Quadrivalent research structure. Results apply only to the specific age groups studied.

What is Still Uncertain About Fluzone Quadrivalent Research

Research still explores many facets of this vaccine. The findings were mixed regarding absolute clinical effectiveness across different seasons and geographic regions. The measured clinical outcome, as opposed to the antibody response, can vary yearly, and this variability is a persistent research question. Comparative evidence is lacking for large-scale, head-to-head clinical trials comparing this standard-dose quadrivalent vaccine against all other non-enhanced quadrivalent products for outcomes beyond immunogenicity. Finally, data for certain groups and the research exploring long-term symptom patterns or effects beyond the single influenza season are not fully established.

Key Studies & References

1. Fluzone Quadrivalent (Influenza Vaccine) Injectable Suspension - DailyMed

Common questions about Fluzone Quadrivalent (FAQ)

Q: What are the four influenza virus strains that Fluzone Quadrivalent is designed to cover?

Fluzone Quadrivalent is specifically designed to target four influenza virus components. The formulation includes antigens from two different Influenza A subtypes and two different Influenza B lineages. These four components align with the circulating strains that public health officials select for that specific season.

Q: Does Fluzone Quadrivalent reduce the severity of flu symptoms in people who still get sick?

The general purpose of the vaccine is to establish protection and mitigate the risk of infection. Official regulatory descriptions indicate that vaccination may not protect every recipient. While the intent is to lessen the impact of the flu, the regulatory documents do not provide a direct guarantee of reduced severity of symptoms for those who still contract the illness.

Q: What signs are associated with a potential severe allergic reaction to Fluzone Quadrivalent?

A potential severe allergic reaction, such as anaphylaxis, is a documented serious event from postmarketing reports. Regulatory information emphasizes that appropriate medical treatment must be immediately available during and following administration. If a severe reaction is suspected, seeking immediate medical care is necessary.

Q: Are there any long-term health concerns or effects associated with Fluzone Quadrivalent?

Research exploring the long-term effects of the vaccine, particularly beyond the single flu season, is not fully established in regulatory documents. However, mandatory postmarketing surveillance records rare, severe neurological events such as Guillain-Barré Syndrome (GBS). The safety profile is continuously monitored based on clinical trial data and these postmarketing reports.

Q: Are children more likely than adults to experience fever or vomiting from Fluzone Quadrivalent than adults?

Clinical trial data shows that fever is a common side effect for both children and adults who receive the vaccine. However, the regulatory documents do not list vomiting among the very common or common systemic adverse reactions solicited in trials for either group.

Q: Is Fluzone Quadrivalent the same formulation as the high-dose flu vaccine used for seniors?

No, Fluzone Quadrivalent is the standard-dose formulation approved for individuals 6 months of age and older. It is a distinct product from the high-dose formulation, which is specifically approved and often used for persons 65 years of age and older.

Q: Can Fluzone Quadrivalent be administered to a person who is pregnant?

The official regulatory labeling indicates that there is only limited human data available to fully assess the potential risk of the vaccine during pregnancy. Due to this limited data, the decision to use the vaccine involves a careful evaluation of the potential benefits versus the risks by a healthcare provider.

Q: Can Fluzone Quadrivalent be used by breastfeeding mothers?

Regulatory information states there are no specific human data regarding the effects of the vaccine during lactation or on the breastfed infant. Official guidance indicates that the vaccine is typically administered to a nursing woman only if the need for the product is clearly defined.

Q: How is the match between the Fluzone Quadrivalent vaccine and circulating flu strains determined?

Fluzone Quadrivalent is formulated annually to include the influenza strains projected to be the most prevalent. This strain selection process is based on recommendations developed by leading global public health officials, such as the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA), to best match the circulating strains.

Q: What is the general likelihood of a rare side effect, such as GBS, occurring after Fluzone Quadrivalent?

The connection between Guillain-Barré Syndrome (GBS) and the flu vaccine is a recognized area of caution. Regulatory documents note that if an excess risk of GBS exists, the expected rate is very low, estimated to be slightly more than one additional case per one million persons who receive the vaccine.

Q: What is the main reason why the flu vaccine formula needs to be updated annually?

There are two main reasons why the vaccine formulation is updated yearly. First, the protective immunity established by the vaccine gradually declines within the year after administration. Second, the strains of influenza virus circulating change from year to year, requiring the vaccine to be reformulated to match the current threats.

Q: What are the known differences in side effect rates between adults and children who receive Fluzone Quadrivalent?

Clinical trial data shows differences in the most common systemic reactions between age groups. In children 6 months through 35 months, very common systemic reactions include irritability and drowsiness. In adults 18 years and older, the most common systemic reactions are headache and myalgia (muscle aches).

Q: Why is it recommended that people receive Fluzone Quadrivalent every year?

Annual vaccination is recommended because the protection established by the vaccine tends to decline within the year. Furthermore, the circulating influenza virus strains often change from year to year, requiring a newly formulated vaccine to match the current threats.

Q: How long can common side effects like muscle aches or headache last after the Fluzone Quadrivalent shot?

The most frequently reported side effects, which include muscle aches, headache, and injection site pain, are generally mild and temporary. Clinical trial data indicates that the majority of these solicited local and systemic reactions resolved within three days following the vaccination.

Q: Does Fluzone Quadrivalent contain thimerosal (a mercury-containing preservative)?

The presence of the preservative thimerosal, which contains mercury, depends on the vaccine format. Regulatory information states that the single-dose syringes and single-dose vials are manufactured to be thimerosal-free. Multi-dose vials, however, may contain thimerosal as a preservative.

Q: Are there restrictions on getting Fluzone Quadrivalent if a person has a mild cold or nasal congestion?

Generally, official guidance states that individuals can still receive the vaccine if they have a minor illness, such as a mild cold or nasal congestion, without a fever. If a person has a more severe, acute illness with a high fever or infection, official guidance generally advises waiting until those severe symptoms have improved.

Q: What is the definition of a 'serious adverse event' as reported in the clinical trials for Fluzone Quadrivalent?

In clinical trials, participants were monitored for different types of adverse events over different periods. Serious adverse events (SAEs) were specifically monitored during the six months following the last dose of the vaccine, while other unsolicited events were monitored for a shorter 28-day period.

Q: Is Fluzone Quadrivalent available in a pre-filled syringe or only in multi-dose vials?

Fluzone Quadrivalent is supplied in multiple forms for administration. Regulatory documents confirm that it is available in prefilled single-dose syringes and single-dose vials, in addition to multi-dose vials.

Q: Does the injection site reaction from Fluzone Quadrivalent feel like a hard lump sometimes?

Official guidance on injection site reactions indicates that it is possible for a localized reaction to include the feeling of a hard lump, in addition to pain and redness. This occurs alongside other common injection site symptoms.

Q: Is Fluzone Quadrivalent recommended for people with a history of fainting (syncope) after previous injections?

Syncope, or fainting, has been reported in individuals following the administration of the vaccine. Official guidance states that procedures should be in place to minimize the risk of injury if a person experiences syncope (fainting) during or immediately after the injection.

Q: Are there different recommendations for Fluzone Quadrivalent usage depending on hemisphere (e.g., Northern vs. Southern)?

Yes, there are different formulations of the vaccine used in different geographic regions. Regulatory documents confirm that a separate formulation, such as Fluzone Quadrivalent Southern Hemisphere, is specifically designed and approved for use in the Southern Hemisphere.

Fluzone Quadrivalent must be stored in a refrigerator between 2°C and 8°C (36°F and 46°F). It is critical to protect the vaccine from freezing. If the vaccine has been frozen, it must be discarded as freezing can cause loss of potency. The vaccine should also be protected from light.

Vaccine must not be used after the expiration date printed on the label. Discard any unused portions of single-dose vials or syringes. For multi-dose vials, refer to the manufacturer's specific instructions for the duration the vial can be used after the first dose is withdrawn.

Disposal of any expired, unused, or frozen vaccine should be done in accordance with applicable local regulations for medical waste or by returning it to a pharmacy or healthcare provider for safe disposal.